Drug Database · Clinicians

Cilastatin + Imipenem

Brands (16) BDIMI-C 250, BDIMI-C 500, Imasan…Show all

US brand (reference label): PRIMAXIN IV; not a Philippine-registered brand.

Antibacterial (carbapenem Beta-Lactamase)/Dehydropeptidase inhibitor; Antibacterial (carbapanem); and others PH FDA category
Fixed-dose combination.

Reduce below CrCl 90; avoid <15 off HDRx · Prescription drug16 PH products Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID f41d8abd-7792-4918-1b93-bd83ea01955e, version date July 5, 2024 (PRIMAXIN IV · Merck Sharp & Dohme LLC). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • PRIMAXIN for intravenous use is a combination of imipenem, a penem antibacterial, and cilastatin, a renal dehydropeptidase inhibitor, indicated for the treatment of the following serious infections caused by designated…
  • Urinary tract infections.
  • Intra-abdominal infections.
  • Gynecologic infections.
  • Bacterial septicemia.
  • Bone and joint infections.
  • Skin and skin structure infections.
  • Endocarditis.
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE PRIMAXIN for intravenous use is a combination of imipenem, a penem antibacterial, and cilastatin, a renal dehydropeptidase inhibitor, indicated for the treatment of the following serious infections caused by designated susceptible bacteria: Lower respiratory tract infections. (1.1) Urinary tract infections.

(1.2) Intra-abdominal infections. (1.3) Gynecologic infections. (1.4) Bacterial septicemia. (1.5) Bone and joint infections. (1.6) Skin and skin structure infections. (1.7) Endocarditis. (1.8) Limitations of Use: PRIMAXIN is not indicated in patients with meningitis because safety and efficacy have not been established (1.9).

PRIMAXIN is not recommended in pediatric patients with CNS infections because of the risk of seizures (1.9). PRIMAXIN is not recommended in pediatric patients weighing less than 30 kg with impaired renal function (1.9). Usage: To reduce the development of drug resistant bacteria and maintain the effectiveness of PRIMAXIN and other antibacterial drugs, PRIMAXIN should be used only to treat infections that are proven or strongly suspected to be caused by bacteria (1.10). 1.1 Lower Respiratory Tract Infections PRIMAXIN for intravenous use is indicated for the treatment of lower respiratory tract infections caused by susceptible strains of Staphylococcus aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, Escherichia coli, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella species, Serratia marcescens. 1.2 Urinary Tract Infections (complicated and uncomplicated) PRIMAXIN is indicated for the treatment of urinary tract infections (complicated and uncomplicated) caused by susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Enterobacter species, Escherichia coli, Klebsiella species, Morganella morganii, Proteus vulgaris, Providencia rettgeri, Pseudomonas aeruginosa. 1.3 Intra-Abdominal Infections PRIMAXIN is indicated for the treatment of intra-abdominal infections caused by susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Staphylococcus epidermidis, Citrobacter species, Enterobacter species, Escherichia coli, Klebsiella species, Morganella morganii, Proteus species, Pseudomonas aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species including B. fragilis, Fusobacterium species. 1.4 Gynecologic Infections PRIMAXIN is indicated for the treatment of gynecologic infections caused by susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Staphylococcus epidermidis, Streptococcus agalactiae (Group B streptococci), Enterobacter species, Escherichia coli, Gardnerella vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species including B. fragilis. 1.5 Bacterial Septicemia PRIMAXIN is indicated for the treatment of bacterial septicemia caused by susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Enterobacter species, Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, Serratia species, Bacteroides species including B. fragilis. 1.6 Bone and Joint Infections PRIMAXIN is indicated for the treatment of bone and joint infections caused by susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Staphylococcus epidermidis, Enterobacter species, Pseudomonas aeruginosa. 1.7 Skin and Skin Structure Infections PRIMAXIN is indicated for the treatment of skin and skin structure infections caused by susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Staphylococcus epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, Escherichia coli, Klebsiella species, Morganella morganii, Proteus vulgaris, Providencia rettgeri, Pseudomonas aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species including B. fragilis, Fusobacterium species. 1.8 Endocarditis PRIMAXIN is indicated for the treatment of endocarditis caused by susceptible strains of Staphylococcus aureus (penicillinase-producing isolates). 1.9 Limitations of Use PRIMAXIN is not indicated in patients with meningitis because safety and efficacy have not been established.

PRIMAXIN is not recommended in pediatric patients with CNS infections because of the risk of seizures [see Dosage and Administration (2.2), Warnings and Precautions (5.2), and Use in Specific Populations (8.4)]. PRIMAXIN is not recommended in pediatric patients less than 30 kg with impaired renal function, as no data are available [see Use in Specific Populations (8.4), and Dosage and Administration (2.2)].

Periodic assessment of organ system functions, including renal, hepatic and hematopoietic, is advisable during prolonged therapy. 1.10 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of PRIMAXIN and other antibacterial drugs, PRIMAXIN should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.

In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Contraindications

  • Hypersensitivity to any component
renalcarematters.com, reviewed
Contraindications (US label) US FDA label

4 CONTRAINDICATIONS PRIMAXIN is contraindicated in patients who have shown hypersensitivity to any component of this product. Known hypersensitivity to any component of PRIMAXIN (4)

Dosing: Adult

  • Susceptible organisms (CrCl 90 or more): 500 mg every 6 hours or 1 g every 8 hours IV
  • Intermediate susceptibility: 1 g every 6 hours IV
  • Maximum: 4 g/day
  • Infusion: 500 mg over 20 to 30 minutes; 1 g over 40 to 60 minutes
renalcarematters.com, reviewed
Dosage and administration (US label) US FDA label

The dosage of PRIMAXIN in adult patients should be based on suspected or confirmed pathogen susceptibility (2.1). For adult patients with normal renal function (creatinine clearance of greater than or equal to 90 mL/min), the recommended dosage regimens are: 500 mg every 6 hours OR 1000 mg every 8 hours OR 1000 mg every 6 hours (2.1).

See full prescribing information for dosage recommendations in pediatric patients (2.2). A reduction in dose must be made for a patient with a creatinine clearance of less than 90 mL/min (2.3). Patients with creatinine clearances of less than 15 mL/min should not receive PRIMAXIN unless hemodialysis is instituted within 48 hours (2.4).

Reconstitute PRIMAXIN vial with appropriate diluent and dilute the reconstituted suspension with an appropriate infusion solution before administering by intravenous infusion (2.5).

2.1 Dosage in Adults For Intravenous Injection Only

2.1 Dosage in Adults For Intravenous Injection Only The dosage of PRIMAXIN in adult patients should be based on suspected or confirmed pathogen susceptibility as shown in Table 1 below. The dosage recommendations for PRIMAXIN represent the quantity of imipenem to be administered. An equivalent amount of cilastatin is also present in the solution.

These doses should be used for patients with creatinine clearance of greater than or equal to 90 mL/min. A reduction in dose must be made for patients with creatinine clearance less than 90 mL/min as shown in Table 3 [see Dosage and Administration (2.3)]. Recommend that the maximum total daily dosage not exceed 4 g/day. Administer 500 mg by intravenous infusion over 20 to 30 minutes.

Administer 1000 mg by intravenous infusion over 40 to 60 minutes. In patients who develop nausea during the infusion, the rate of infusion may be slowed. Table 1: Dosage of PRIMAXIN in Adult Patients with Creatinine Clearance Greater than or Equal to 90 mL/min Suspected or Proven Pathogen Susceptibility Dosage of PRIMAXIN If the infection is suspected or proven to be due to a susceptible bacterial species 500 mg every 6 hours OR 1000 mg every 8 hours If the infection is suspected or proven to be due to bacterial species with intermediate susceptibility [see Microbiology (12.4)] 1000 mg every 6 hours

2.2 Dosage in Pediatric Patients

2.2 Dosage in Pediatric Patients PRIMAXIN is not recommended in pediatric patients with CNS infections because of the risk of seizures [see Use in Specific Populations (8.4)]. PRIMAXIN is not recommended in pediatric patients <30 kg with renal impairment, as no data are available [see Use in Specific Populations (8.4)].

Based on studies in adults, the maximum total daily dose in pediatric patients should not exceed 4 g/day [see Dosage and Administration (2.1)]. The recommended dosage for pediatric patients with non-CNS infections is shown in Table 2 below: Table 2: Recommended PRIMAXIN Dosage in Pediatric Patients for Non-CNS Infections Age Dose (mg/kg) Doses less than or equal to 500 mg should be given by intravenous infusion over 20 to 30 minutes, Doses greater than 500 mg should be given by intravenous infusion over 40 to 60 minutes Recommend that the maximum total daily dosage not exceed 4g/day Frequency (hours) Greater than or equal to 3 Months of Age 15-25 mg/kg Every 6 hours Less than or equal to 3 months of age (Greater than or equal to 1,500 g body weight) 4 weeks to 3 months of age 25 mg/kg Every 6 hours 1 to 4 weeks of age 25 mg/kg Every 8 hours Less than 1 week of age 25 mg/kg Every 12 hours

2.3 Dosage in Adult Patients with Renal Impairment

2.3 Dosage in Adult Patients with Renal Impairment Patients with creatinine clearance less than 90 mL/min require dosage reduction of PRIMAXIN as indicated in Table 3. The serum creatinine should represent a steady state of renal function. Use the Cockcroft-Gault method described below to calculate the creatinine clearance: Males: (weight in kg) × (140-age in years) (72) × serum creatinine (mg/100 mL) Females: (0.85) × (value calculated for males) Table 3: Dosage of PRIMAXIN for Adult Patients in Various Renal Function Groups Based on Estimated Creatinine Clearance (CLcr) Creatinine clearance (mL/min) Greater than or equal to 90 Less than 90 to greater than or equal to 60 Less than 60 to greater than or equal to 30 Less than 30 to greater than or equal to 15 Dosage of PRIMAXIN Administer doses less than or equal to 500 mg by intravenous infusion over 20 to 30 minutes.

Discard unused portion of the infusion solution., Administer doses greater than 500 mg by intravenous infusion over 40 to 60 minutes. In patients who develop nausea during the infusion, the rate of infusion may be slowed. If the infection is suspected or proven to be due to a susceptible bacterial species: 500 mg every 6 hours 400 mg every 6 hours 300 mg every 6 hours 200 mg every 6 hours OR 1000 mg every 8 hours 500 mg every 6 hours 500 mg every 8 hours 500 mg every 12 hours Dosage of PRIMAXIN, If the infection is suspected or proven to be due to bacterial species with intermediate susceptibility [see Microbiology (12.4)]: 1000 mg every 6 hours 750 mg every 8 hours 500 mg every 6 hours 500 mg every 12 hours In patients with creatinine clearances of less than 30 to greater than or equal to 15 mL/min, there may be an increased risk of seizures [see Warnings and Precautions (5.2) and Use in Specific Populations (8.6)].

Patients with creatinine clearance less than 15 mL/min should not receive PRIMAXIN unless hemodialysis is instituted within 48 hours. There is inadequate information to recommend usage of PRIMAXIN for patients undergoing peritoneal dialysis.

2.4 Dosage in Hemodialysis Patients

2.4 Dosage in Hemodialysis Patients When treating patients with creatinine clearances of less than 15 mL/min who are undergoing hemodialysis, use the dosage recommendations for patients with creatinine clearances of less than 30 to greater than or equal to 15 mL/min in Table 3 above [see Dosage and Administration (2.3)]. Both imipenem and cilastatin are cleared from the circulation during hemodialysis.

The patient should receive PRIMAXIN after hemodialysis and at intervals timed from the end of that hemodialysis session. Dialysis patients, especially those with background CNS disease, should be carefully monitored; for patients on hemodialysis, PRIMAXIN is recommended only when the benefit outweighs the potential risk of seizures [see Warnings and Precautions (5.2)].

2.5 Reconstitution and Preparation

2.5 Reconstitution and Preparation of PRIMAXIN Solution for Intravenous Administration PRIMAXIN Vials Do not use diluents containing benzyl alcohol to reconstitute PRIMAXIN for administration to neonates because it has been associated with toxicity in neonates. While toxicity has not been demonstrated in pediatric patients greater than three months of age, small pediatric patients in this age range may also be at risk for benzyl alcohol toxicity.

Contents of the vials must be reconstituted by adding approximately 10 mL of the appropriate diluent to the vial. List of appropriate diluents are as follows: 0.9% Sodium Chloride Injection 5% Dextrose Injection 5% Dextrose and 0.9% Sodium Chloride Injection 5% Dextrose Injection with 0.225% or 0.45% saline solution Reconstituted Solutions of PRIMAXIN range from colorless to yellow.

Variations of color within this range do not affect the potency of the product. The reconstituted suspension must not be administered by direct Intravenous Infusion After reconstitution, shake vial well and transfer the resulting suspension to 100 mL of an appropriate infusion solution before administering by intravenous infusion.

Repeat transfer of the resulting suspension with an additional 10 mL of infusion solution to ensure complete transfer of vial contents to the infusion solution. Agitate the resulting mixture until clear. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Discard unused portion of the infusion solution where applicable.

2.6 Storage of Reconstituted Solutions Vials (After

2.6 Storage of Reconstituted Solutions Vials (After Reconstitution) PRIMAXIN, as supplied in single dose vials and reconstituted with the appropriate diluents [see Dosage and Administration (2.5)], maintains satisfactory potency for 4 hours at room temperature or for 24 hours under refrigeration (5°C). Do not freeze solutions of PRIMAXIN.

2.7 Incompatibility and Compatibility

2.7 Incompatibility and Compatibility of PRIMAXIN with other Antibacterial Drugs Do not mix PRIMAXIN with, or physically add to, other antibacterial drugs. PRIMAXIN may be administered concomitantly with other antibacterial drugs, such as aminoglycosides.

Dosing: Altered kidney function

Imipenem and cilastatin are each about 70% recovered in urine. The US label reduces the dose once creatinine clearance (CrCl) falls below 90 mL/min, raises the seizure warning at CrCl below 30, and says not to give it at CrCl below 15 unless hemodialysis starts within 48 hours. On hemodialysis, use the CrCl 15–29 doses after each session, only when benefit outweighs seizure risk.

Kidney function measure: Label uses CrCl (mL/min; Cockcroft–Gault); bands at 90, 60, 30 and 15.

Show full dosing details
CrCl ≥60 mL/min
CrCl 90 or more: 500 mg every 6 hours or 1 g every 8 hours (susceptible), 1 g every 6 hours (intermediate). CrCl 60–89: 400 mg every 6 hours or 500 mg every 6 hours (susceptible); 750 mg every 8 hours (intermediate) (label Table 3).
CrCl 30–59 mL/min
CrCl 30–59: 300 mg every 6 hours or 500 mg every 8 hours (susceptible); 500 mg every 6 hours (intermediate) (label Table 3).
CrCl 15–29 mL/min
CrCl 15–29: 200 mg every 6 hours or 500 mg every 12 hours (susceptible); 500 mg every 12 hours (intermediate). Seizure risk may be higher (label Table 3).
CrCl <15 mL/min (not on dialysis)
CrCl below 15: do not give unless hemodialysis is started within 48 hours (label).
Hemodialysis (intermittent)
Use the CrCl 15–29 doses (200 mg every 6 hours or 500 mg every 12 hours; 500 mg every 12 hours for intermediate organisms). Give after hemodialysis and time later doses from the end of the session. Recommended only when benefit outweighs seizure risk; monitor closely, especially with CNS disease (label).
Peritoneal dialysis
Information is inadequate to recommend use in peritoneal dialysis (label). For PD-associated peritonitis (ISPD 2022): intraperitoneal intermittent 500 mg in alternate exchanges; continuous loading dose 250 mg/L, then 50 mg/L in each exchange. Specialist input.
CRRT
Not in label. Li 2020 (Table 3): CVVH ultrafiltration 52 ± 14 mL/kg/h, 1 g every 6 hours; CVVH, CVVHD or CVVHDF at 20 or 37 mL/kg/h, 500 mg every 6 hours for MIC 2 mg/L or less and 1 g every 6 hours for MIC 4–16 mg/L.
  • Dialyzable? Yes: imipenem and cilastatin are both cleared by hemodialysis (label). Protein binding: imipenem about 20%, cilastatin about 40%.
  • Monitoring CrCl for dose; seizures, myoclonus and confusion, especially at CrCl 30 or less, on dialysis, or with CNS disease (label); valproate levels if coadministered.
Children (kidney dosing)
Show full dosing details
eGFR ≥60
Usual weight-based dose (label).
eGFR 30–59
Not recommended in children under 30 kg with kidney impairment (no data). 30 kg or more: no pediatric dosing given; specialist input (label).
eGFR 15–29
Not recommended in children under 30 kg with kidney impairment (no data). 30 kg or more: no pediatric dosing given; specialist input (label).
eGFR <15 (not on dialysis)
Not recommended in children under 30 kg with kidney impairment (no data). 30 kg or more: no pediatric dosing given; specialist input (label).
Hemodialysis (intermittent)
Not recommended in children under 30 kg with kidney impairment (no data) (label). Specialist input.
Peritoneal dialysis
Not recommended in children under 30 kg with kidney impairment (no data) (label). Specialist input.
CRRT
Not recommended in children under 30 kg with kidney impairment (no data) (label). Specialist input.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

US label text: Renal impairment US FDA label

2.3 Dosage in Adult Patients with Renal Impairment Patients with creatinine clearance less than 90 mL/min require dosage reduction of PRIMAXIN as indicated in Table 3. The serum creatinine should represent a steady state of renal function. Use the Cockcroft-Gault method described below to calculate the creatinine clearance: Males: (weight in kg) × (140-age in years) (72) × serum creatinine (mg/100 mL) Females: (0.85) × (value calculated for males) Table 3: Dosage of PRIMAXIN for Adult Patients in Various Renal Function Groups Based on Estimated Creatinine Clearance (CLcr) Creatinine clearance (mL/min) Greater than or equal to 90 Less than 90 to greater than or equal to 60 Less than 60 to greater than or equal to 30 Less than 30 to greater than or equal to 15 Dosage of PRIMAXIN Administer doses less than or equal to 500 mg by intravenous infusion over 20 to 30 minutes.

Discard unused portion of the infusion solution., Administer doses greater than 500 mg by intravenous infusion over 40 to 60 minutes. In patients who develop nausea during the infusion, the rate of infusion may be slowed. If the infection is suspected or proven to be due to a susceptible bacterial species: 500 mg every 6 hours 400 mg every 6 hours 300 mg every 6 hours 200 mg every 6 hours OR 1000 mg every 8 hours 500 mg every 6 hours 500 mg every 8 hours 500 mg every 12 hours Dosage of PRIMAXIN, If the infection is suspected or proven to be due to bacterial species with intermediate susceptibility [see Microbiology (12.4)]: 1000 mg every 6 hours 750 mg every 8 hours 500 mg every 6 hours 500 mg every 12 hours In patients with creatinine clearances of less than 30 to greater than or equal to 15 mL/min, there may be an increased risk of seizures [see Warnings and Precautions (5.2) and Use in Specific Populations (8.6)].

Patients with creatinine clearance less than 15 mL/min should not receive PRIMAXIN unless hemodialysis is instituted within 48 hours. There is inadequate information to recommend usage of PRIMAXIN for patients undergoing peritoneal dialysis.

2.4 Dosage in Hemodialysis Patients When treating patients with creatinine clearances of less than 15 mL/min who are undergoing hemodialysis, use the dosage recommendations for patients with creatinine clearances of less than 30 to greater than or equal to 15 mL/min in Table 3 above [see Dosage and Administration (2.3)]. Both imipenem and cilastatin are cleared from the circulation during hemodialysis.

The patient should receive PRIMAXIN after hemodialysis and at intervals timed from the end of that hemodialysis session. Dialysis patients, especially those with background CNS disease, should be carefully monitored; for patients on hemodialysis, PRIMAXIN is recommended only when the benefit outweighs the potential risk of seizures [see Warnings and Precautions (5.2)].

8.6 Renal Impairment Dosage adjustment is necessary in patients with renal impairment [see Dosage and Administration (2.3)]. Adult patients with creatinine clearances of less than or equal to 30 mL/min, whether or not undergoing hemodialysis, had a higher risk of seizure activity than those without impairment of renal function [see Warnings and Precautions (5.2)]. Therefore, close adherence to the dosing guidelines and regular monitoring of creatinine clearance for these patients is recommended.

Dosing: Pediatric

Approved ages
Neonates and children (non-CNS infections); not recommended for CNS infections (label).
Usual dose
Up to 3 months (1,500 g or more): under 1 week 25 mg/kg every 12 hours; 1–4 weeks 25 mg/kg every 8 hours; 4 weeks to 3 months 25 mg/kg every 6 hours (label). 3 months and older: 15 to 25 mg/kg every 6 hours (label).
Maximum dose
4 g/day (label).

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed
Pediatric use (US label) US FDA label

8.4 Pediatric Use Use of PRIMAXIN in pediatric patients is supported by evidence from adequate and well-controlled trials of PRIMAXIN in adults and clinical studies in pediatric patients [see Dosage and Administration (2.2) and Clinical Pharmacology (12.3)]. PRIMAXIN is not recommended in pediatric patients with CNS infections because of the risk of seizures. PRIMAXIN is not recommended in pediatric patients less than 30 kg with renal impairment, as no data are available.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Of the approximately 3600 subjects ≥18 years of age in clinical studies of PRIMAXIN, including postmarketing studies, approximately 2800 received PRIMAXIN. Of the subjects who received PRIMAXIN, data are available on approximately 800 subjects who were 65 and over, including approximately 300 subjects who were 75 and over.

No overall differences in safety or effectiveness were observed between these subjects and younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.

Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. No dosage adjustment is required based on age [see Clinical Pharmacology (12.3)]. Dosage adjustment in the case of renal impairment is necessary [see Dosage and Administration (2.3)].

Administration

2.5 Reconstitution and Preparation of PRIMAXIN Solution for Intravenous Administration PRIMAXIN Vials Do not use diluents containing benzyl alcohol to reconstitute PRIMAXIN for administration to neonates because it has been associated with toxicity in neonates. While toxicity has not been demonstrated in pediatric patients greater than three months of age, small pediatric patients in this age range may also be at risk for benzyl alcohol toxicity. Contents of the vials must be reconstituted by adding approximately 10 mL of the appropriate diluent to the vial. List of appropriate diluents are as follows : 0.9% Sodium Chloride Injection 5% Dextrose Injection 5% Dextrose and 0.9% Sodium Chloride Injection 5% Dextrose Injection with 0.225% or 0.45% saline solution Reconstituted Solutions of PRIMAXIN range from colorless to yellow. Variations of color within this range do not affect the potency of the product. The reconstituted suspension must not be administered by direct Intravenous Infusion After reconstitution, shake vial well and transfer the resulting suspension to 100 mL of an appropriate infusion solution before administering by intravenous infusion. Repeat transfer of the resulting suspension with an additional 10 mL of infusion solution to ensure complete transfer of vial contents to the infusion solution. Agitate the resulting mixture until clear. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Discard unused portion of the infusion solution where applicable.

2.6 Storage of Reconstituted Solutions Vials (After Reconstitution) PRIMAXIN, as supplied in single dose vials and reconstituted with the appropriate diluents [see Dosage and Administration (2.5) ] , maintains satisfactory potency for 4 hours at room temperature or for 24 hours under refrigeration (5°C). Do not freeze solutions of PRIMAXIN.

2.7 Incompatibility and Compatibility of PRIMAXIN with other Antibacterial Drugs Do not mix PRIMAXIN with, or physically add to, other antibacterial drugs. PRIMAXIN may be administered concomitantly with other antibacterial drugs, such as aminoglycosides.

US FDA label

Dosage forms

Philippines

  • Powder for injection: 250 mg/250 mg, 500 mg, 500 mg/500 mg
  • Powder for solution for infusion: 500 mg/500 mg

Registered products in the Philippines

16 products registered with the Food and Drug Administration (FDA) Philippines list Cilastatin + Imipenem as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products16
Philippine FDA-registered products for Cilastatin + Imipenem
Package insert
BDIMI-C 250Imipenem + Cilastatin Sodium
250 mg/250 mg Powder for Injection (I.V.)20 mL USP Type I Glass Vial Box of 1’s
Rx
Mepromax Lifesciences Pvt. Ltd.India
Ambica International CorporationTrader: BDR Pharmaceuticals International Pvt. Ltd.
DRP-9909
Nov 20, 2029
BDIMI-C 500Imipenem + Cilastatin Sodium
500 mg/500 mg Powder for Injection (IV)20 mL USP Type I Glass Vial (Box of 1’s)
Rx
Mepromax Lifesciences Pvt. Ltd.India
Ambica International CorporationTrader: BDR Pharmaceuticals International Pvt. Ltd.
DRP-9878
Nov 20, 2029
ImasanImipenem+Cilastatin (as sodium)
500 mg/500 mg Powder for Injection (I.V.)USP Type I Clear Glass Vial with green flip-off Seal x 30 mL Box of 1's
Rx
ZEISS PHARMACEUTICALS PVT. LTD.India
SRS LIFE SCIENCES, INC.Importer: SRS LIFE SCIENCES INC.
DRP-2803
Feb 16, 2029
ImaxinImipenem (as monohydrate) + Cilastatin (as sodium)
500 mg/500 mg Powder for Injection (I.V.)USP Type I Clear Glass Vial with Grey Bromo Butyl Rubber Stopper and Green Flip-Off Seal (Box of 1's and 10's)
Rx
CSPC Ouyi Pharmaceutical Co., Ltd.China
AMB HK ENTERPRISES INC.
DRP-10908
Dec 15, 2031
ImiclastImipenem +Cilastatin Sodium
500 mg/ 500 mg Powder for Solution for Infusion (I.V.)Clear Glass Type I Vial x 30 mL (Box of l’s)
Rx
PT. Novell Pharmaceutical LaboratoriesIndonesia
Prosweal Healthcare Inc.
DR-XY48211
Jul 22, 2027
Imilion-C PlusImipenem + Cilastatin
500 mg/ 500 mg Powder for Injection (IV/IM)30 mL USP Type III Glass Vial with 20 mm Grey Butyl Rubber Stopper and Flip-Off Seal (Box of 1's)
Rx
Stallion Laboratories Pvt. Ltd.India
Ambica International Corporation
DRP-4784
Oct 11, 2028
Imiwel-C 250Imipenem + Cilastatin Sodium
250 mg/250 mg Powder for Injection (IV)USP Type I Glass Vial x 30 mL (Box of 1's)
Rx
Zeiss Pharmaceuticals Pvt. LimitedIndia
Ambica International Corporation
DRP-4648
Sep 2, 2028
Imiwel-C 500Imipenem + Cilastatin (As Sodium)
500 mg/ 500 mg Powder for Injection (IV)USP Type I clear glass vial (Box of 1's)
Rx
Zeiss Pharmaceuticals Pvt. LimitedIndia
Ambica International Corporation
DRP-6000
Feb 10, 2030
ImlastinImipenem + Cilastatin (as Sodium)
500 mg/500 mg Powder for Injection (IV)USP Type I Vial x 20 mL Box of 1's
Rx
Swiss Parenterals Ltd.India
Endure Medical, Inc.
DR-XY43649
Aug 19, 2029
Lastpen-1GmImipenem + Cilastatin (as sodium)
500 mg/500 mg Powder For Injection (IV)USP-Type I Glass Vial x 30 mL (Box of 1's)
Rx
BRAWN LABORATORIES LIMITEDIndia
Bliss Pharma Distribution and Consultancy Corp.
DRP-18622
Aug 13, 2031
LykaspetinImipenem (as monohydrate) + Cilastatin (as sodium)
500 mg/500 mg Powder for injection (I.V.)30 mL - Capacity USP Type I Clear and Colorless Glass Vial (Box of 1 Vial placed in White Plastic Tray)
Rx
Lyka Labs LimitedIndia
Ambica International Corporation
DRP-6665
Apr 27, 2038
NimedineImipenem (as monohydrate) + Cilastatin (as sodium)
500 mg/500 mg Powder for Injection (IV)20 mL-Capacity Type III Glass Vial with Bromobutyl Rubber Stopper and Aluminum Cap with Plastic Flip-Off Seal (Box of 1’s)
Rx
Anfarm Hellas S.A.Greece
Saifen Drugs Philippines Inc.
DRP-16072
Aug 15, 2031
SeamilastImipenem + Cilastatin
500mg/500mg Powder for Injection (IV)USP Type-I Clear Glass Vial x 20 mL (Box of 1’s)
Rx
Brooks Laboratories LimitedIndia
Seapharma International, Inc.
DRP-11891
May 17, 2027
TieMacImipenem + Cilastatin (as sodium)
500 mg/500 mg Powder for Injection (I.V./I.M.)20 mL USP Type I Clear Glass Vial (Box of 10's)
Rx
Myungmoon Pharmaceutical Co., Ltd.Republic of Korea
Remker Drug, Inc.Importer: H & B Pharma International Inc.
DRP-7262
Nov 18, 2028
TienamImipenem + Cilastatin
500 mg Powder for Injection (IV)
Rx
MERCK SHARP & DOHME CORP.
Importer: MERCK SHARP & DOHME (I.A.) LLC
DR-XY13460
Jan 18, 2027
VEXPINEM 500Imipenem + Cilastatin
500 mg/500 mg Powder for Injection (I.V.)Type I Clear glass vial with 20mm grey butyl rubber plug, crimpled aluminum with green flip-off seal (Box of 1's)
Rx
VENUS REMEDIES LIMITEDIndia
VE PHARMA INC.Trader: VEXXA LIFESCIENCES PVT. LTD.
DR-XY46390
Jun 26, 2028

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS For Injection PRIMAXIN is a sterile powder mixture for reconstitution in single-dose containers including vials containing: 500 mg imipenem (anhydrous equivalent) and 500 mg cilastatin (free acid equivalent) For Injection: PRIMAXIN is a sterile powder mixture for reconstitution in single-dose containers including vials containing: 500 mg imipenem (anhydrous equivalent) and 500 mg cilastatin (free acid equivalent) (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label

Hypersensitivity Reactions: Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving therapy with beta-lactams. If an allergic reaction to PRIMAXIN occurs, discontinue the drug immediately (5.1). Seizure Potential: Seizures and other CNS adverse reactions, such as confusional states and myoclonic activity, have been reported during treatment with PRIMAXIN.

If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of PRIMAXIN re-examined to determine whether it should be decreased, or the antibacterial drug discontinued (5.2). Increased Seizure Potential Due to Interaction with Valproic Acid: Co-administration of PRIMAXIN, to patients receiving valproic acid or divalproex sodium results in a reduction in valproic acid concentrations.

The valproic acid concentrations may drop below the therapeutic range as a result of this interaction, therefore increasing the risk of breakthrough seizures. The concomitant use of PRIMAXIN and valproic acid/divalproex sodium is generally not recommended (5.3, 7.3). Clostridioides difficile-Associated Diarrhea (CDAD): has been reported with use of PRIMAXIN and may range in severity from mild diarrhea to fatal colitis.

Evaluate if diarrhea occurs (5.4).

5.1 Hypersensitivity Reactions

5.1 Hypersensitivity Reactions Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving therapy with beta-lactams. These reactions are more likely to occur in individuals with a history of sensitivity to multiple allergens. There have been reports of individuals with a history of penicillin hypersensitivity who have experienced severe hypersensitivity reactions when treated with another beta-lactam.

Before initiating therapy with PRIMAXIN, careful inquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins, other beta-lactams and other allergens. If an allergic reaction to PRIMAXIN occurs, discontinue the drug immediately. Serious anaphylactic reactions require immediate emergency treatment as clinically indicated.

5.2 Seizure Potential

5.2 Seizure Potential Seizures and other CNS adverse experiences, such as confusional states and myoclonic activity, have been reported during treatment with PRIMAXIN, especially when recommended dosages were exceeded [see Adverse Reactions (6.1, 6.2)]. These experiences have occurred most commonly in patients with CNS disorders (e.g., brain lesions or history of seizures) and/or compromised renal function [see Use in Specific Populations (8.6)].

However, there have been reports of CNS adverse experiences in patients who had no recognized or documented underlying CNS disorder or compromised renal function. Anticonvulsant therapy should be continued in patients with known seizure disorders. If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of PRIMAXIN re-examined to determine whether it should be decreased, or the antibacterial drug discontinued.

5.3 Increased Seizure Potential Due to Interaction with Valproic Acid

5.3 Increased Seizure Potential Due to Interaction with Valproic Acid Case reports in the literature have shown that co-administration of carbapenems, including PRIMAXIN, to patients receiving valproic acid or divalproex sodium results in a reduction in valproic acid concentrations. The valproic acid concentrations may drop below the therapeutic range as a result of this interaction, therefore increasing the risk of breakthrough seizures.

Increasing the dose of valproic acid or divalproex sodium may not be sufficient to overcome this interaction. The concomitant use of PRIMAXIN and valproic acid/divalproex sodium is generally not recommended. Antibacterials other than carbapenems should be considered to treat infections in patients whose seizures are well controlled on valproic acid or divalproex sodium.

If administration of PRIMAXIN is necessary, supplemental anti-convulsant therapy should be considered [see Drug Interactions (7.3)]. Close adherence to the recommended dosage and dosage schedules is urged, especially in patients with known factors that predispose to convulsive activity.

5.4 Clostridioides difficile

5.4 Clostridioides difficile -Associated Diarrhea (CDAD) Clostridioides difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including PRIMAXIN, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial drug use.

Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

5.5 Development of Drug-Resistant Bacteria

5.5 Development of Drug-Resistant Bacteria As with other antibacterial drugs, prolonged use of PRIMAXIN may result in overgrowth of nonsusceptible organisms. Repeated evaluation of the patient's condition is essential. If superinfection occurs during therapy, appropriate measures should be taken. Prescribing PRIMAXIN in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

Drug interactions

Drug or classSeverityEffectWhat to do
GanciclovirAvoidGeneralized seizures reported (label).Do not coadminister unless benefit outweighs risk.
ProbenecidAvoidBlocks tubular secretion; higher and longer drug levels (label).Coadministration not recommended.
Valproic acid or divalproexAvoidCarbapenems lower valproate levels below the therapeutic range; breakthrough seizures (label).Generally not recommended; prefer a non-carbapenem.

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed
Drug interactions (US label) US FDA label

Ganciclovir: Generalized seizures have been reported in patients who received ganciclovir. Do not co-administer unless benefit outweighs risk (7.1). Probenecid: Concomitant administration of PRIMAXIN and probenecid results in increases in the plasma level and half-life of imipenem. Concomitant administration is not recommended (7.2).

Valproic acid/divalproex sodium: Concomitant use with PRIMAXIN is generally not recommended. Consider other antibacterial drugs to treat infections in patients whose seizures are well-controlled on valproic acid or divalproex sodium (5.3, 7.3).

7.1 Ganciclovir

7.1 Ganciclovir Generalized seizures have been reported in patients who received ganciclovir and PRIMAXIN. These drugs should not be used concomitantly with PRIMAXIN unless the potential benefits outweigh the risks.

7.2 Probenecid

7.2 Probenecid Concomitant administration of PRIMAXIN and probenecid results in increases in the plasma level and half-life of imipenem. Therefore, it is not recommended that probenecid be given concomitantly with PRIMAXIN.

7.3 Valproic Acid

7.3 Valproic Acid Case reports in the literature have shown that co-administration of carbapenems, including PRIMAXIN, to patients receiving valproic acid or divalproex sodium results in a reduction in valproic acid concentrations. The valproic acid concentrations may drop below the therapeutic range as a result of this interaction, therefore increasing the risk of breakthrough seizures.

Although the mechanism of this interaction is unknown, data from in vitro and animal studies suggest that carbapenems may inhibit the hydrolysis of valproic acid's glucuronide metabolite (VPA-g) back to valproic acid, thus decreasing the serum concentrations of valproic acid [see Warnings and Precautions (5.3)]. The concomitant use of PRIMAXIN and valproic acid/divalproex sodium is generally not recommended.

Antibacterials other than carbapenems should be considered to treat infections in patients whose seizures are well-controlled on valproic acid or divalproex sodium.

Adverse reactions

Common

  • Phlebitis, injection-site pain or erythema
  • Nausea, diarrhea, vomiting
  • Rash, pruritus, fever, hypotension

Serious

  • Anaphylaxis
  • Seizures, myoclonus, confusional states
  • Clostridioides difficile-associated diarrhea
renalcarematters.com, reviewed
Adverse reactions (US label) US FDA label

The following serious adverse reactions are described in greater detail in the Warnings and Precautions section. Hypersensitivity Reactions [see Warnings and Precautions (5.1)] Seizure Potential [see Warnings and Precautions (5.2)] Increased Seizure Potential Due to Interaction with Valproic Acid [see Warnings and Precautions (5.3)] Clostridioides difficile -Associated Diarrhea (CDAD) [see Warnings and Precautions (5.4)] Development of Drug-Resistant Bacteria [see Warnings and Precautions (5.5)] The most frequently occurring adverse reactions (≥0.2%) in adults were phlebitis, nausea, diarrhea, vomiting, rash, pain injection site, fever, hypotension, seizures, erythema at injection site, dizziness, pruritus, vein induration, urticaria, somnolence (6.1).

The most frequently occurring adverse reactions (>1%) in pediatric patients greater than or equal to 3 months of age were diarrhea, rash, phlebitis, gastroenteritis, vomiting, IV site irritation, urine discoloration (6.1). The most frequently occurring adverse reactions (>1%) in neonates to 3 months of age were convulsions, diarrhea, oliguria/anuria, oral candidiasis, rash, tachycardia (6.1).

To report SUSPECTED ADVERSE REACTIONS, contact Merck Sharp & Dohme LLC at 1-877-888-4231 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adult Patients During clinical investigations 1,723 patients were treated with PRIMAXIN.

Table 4 shows the incidence of adverse reactions reported during the clinical investigations of adult patients treated with PRIMAXIN. Table 4: Incidence (%) Adverse reactions with an incidence ≥0.2% of PRIMAXIN-treated adult patients. of Adverse Reactions Reported During Clinical Investigations of Adult Patients Treated with PRIMAXIN Body System Adverse Reactions Frequency (%) Local Administration site Phlebitis/thrombophlebitis 3.1% Pain at the injection site 0.7% Erythema at the injection site 0.4% Vein induration 0.2% Gastrointestinal Nausea 2.0% Diarrhea 1.8% Vomiting 1.5% Skin Rash 0.9% Pruritus 0.3% Urticaria 0.2% Vascular Hypotension 0.4% Body as a Whole Fever 0.5% Nervous system Seizures 0.4% Dizziness 0.3% Somnolence 0.2% Additional adverse reactions reported in less than 0.2% of the patients or reported since the drug was marketed are listed within each body system in order of decreasing severity [see Table 5].

Table 5: Additional Adverse Reactions Occurring in Less than 0.2% of Adult Patients Listed within Each Body System in Order of Decreasing Severity Body System Adverse Reactions Gastrointestinal Pseudomembranous Colitis (the onset of Pseudomembranous colitis symptoms), Hemorrhagic Colitis Gastroenteritis Abdominal Pain Glossitis Tongue Papillar Hypertrophy Heartburn Pharyngeal Pain Increased Salivation CNS Encephalopathy Confusion Myoclonus Paresthesia Vertigo Headache Special Senses Hearing Loss Tinnitus Respiratory Chest Discomfort Dyspnea Hyperventilation Thoracic Spine Pain Cardiovascular Palpitations Tachycardia Skin Erythema Multiforme Angioneurotic Edema Flushing Cyanosis Hyperhidrosis Skin Texture Changes Candidiasis Pruritus Vulvae Local Administration site Infused vein infection Body as a Whole Polyarthralgia Asthenia/Weakness Renal Oliguria/Anuria Polyuria Adverse Laboratory Changes The following adverse laboratory changes were reported during clinical trials: Hepatic: Increased alanine aminotransferase (ALT or SGPT), aspartate aminotransferase (AST or SGOT), alkaline phosphatase, bilirubin, and lactate dehydrogenase (LDH) Hemic: Increased eosinophils, positive Coombs test, increased WBC, increased platelets, decreased hemoglobin and hematocrit, increased monocytes, abnormal prothrombin time, increased lymphocytes, increased basophils Electrolytes: Decreased serum sodium, increased potassium, increased chloride Renal: Increased BUN, creatinine Urinalysis: Presence of urine protein, urine red blood cells, urine white blood cells, urine casts, urine bilirubin, and urine urobilinogen. Pediatric Patients Table 6: Incidence (%) Adverse reactions that occurred in >1% of PRIMAXIN-treated pediatric patients (greater than or equal to 3 months of age) of Adverse Reactions Reported During Clinical Investigations of Pediatric Patients Greater Than or Equal to 3 Months of Age Treated with PRIMAXIN Body System Adverse Reactions Frequency (%) Local Administration Site Phlebitis 2.2% Intravenous Site Irritation 1.1% Gastrointestinal Diarrhea 3.9% Gastroenteritis 1.1% Vomiting 1.1% Skin Rash 2.2% Renal Urine Discoloration 1.1% Table 7: Incidence (%) Adverse reactions that occurred in >1% of PRIMAXIN-treated pediatric patients (neonates to 3 months of age) of Adverse Reactions Reported During Clinical Investigations of Pediatric Patients Neonates to 3 Months of Age Treated with PRIMAXIN Body System Adverse Reactions Frequency (%) Gastrointestinal Diarrhea 3% CNS Convulsions 5.9% Cardiovascular Tachycardia 1.5% Skin Rash 1.5% Body as a Whole Oral Candidiasis 1.5% Renal Oliguria/Anuria 2.2% Adverse Laboratory Changes The following adverse laboratory changes were reported in studies of 178 pediatric patients 3 months of age: increased AST (SGOT), decreased hemoglobin/hematocrit, increased platelets, increased eosinophils, increased ALT (SGPT), increased urine protein, decreased neutrophils.

The following adverse laboratory changes were reported in studies of 135 patients (neonates to 3 months of age): increased eosinophils, increased AST (SGPT), increased serum creatinine, increased/decreased platelet count, increased/decreased bilirubin, increased ALT (SGPT), increased alkaline phosphatase, increased/decreased hematocrit.

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of PRIMAXIN. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Table 8: Adverse Reactions Identified During Post Approval Use of PRIMAXIN Body System Adverse Reactions Gastrointestinal Hepatitis (including fulminant hepatitis) Hepatic failure Jaundice Staining of the teeth and/or tongue Hematologic Pancytopenia Bone marrow depression Thrombocytopenia Neutropenia Leukopenia Hemolytic anemia CNS Tremor Psychic disturbances including hallucinations Dyskinesia Agitation Special Senses Taste perversion Skin Stevens-Johnson syndrome Toxic epidermal necrolysis Body as a whole Drug fever Renal Acute renal failure Urine discoloration Adverse Laboratory Changes Adverse laboratory changes reported since the drug was marketed were: Hematologic: agranulocytosis. Examination of published literature and spontaneous adverse reactions reports suggested a similar spectrum of adverse reactions in adult and pediatric patients.

Adverse reaction frequency tables (US label) US FDA label
Table 4: Incidence (%)Adverse reactions with an incidence ≥0.2% of PRIMAXIN-treated adult patients. of Adverse Reactions Reported During Clinical Investigations of Adult Patients Treated with PRIMAXIN
Body System Adverse Reactions Frequency (%)
Local Administration site Phlebitis/thrombophlebitis 3.1%
Pain at the injection site 0.7%
Erythema at the injection site 0.4%
Vein induration 0.2%
Gastrointestinal Nausea 2.0%
Diarrhea 1.8%
Vomiting 1.5%
Skin Rash 0.9%
Pruritus 0.3%
Urticaria 0.2%
Vascular Hypotension 0.4%
Body as a Whole Fever 0.5%
Nervous system Seizures 0.4%
Dizziness 0.3%
Somnolence 0.2%
Table 5: Additional Adverse Reactions Occurring in Less than 0.2% of Adult Patients Listed within Each Body System in Order of Decreasing Severity
Body System Adverse Reactions
Gastrointestinal Pseudomembranous Colitis (the onset of Pseudomembranous colitis symptoms), Hemorrhagic Colitis
Gastroenteritis
Abdominal Pain
Glossitis
Tongue Papillar
Hypertrophy
Heartburn
Pharyngeal Pain
Increased Salivation
CNS Encephalopathy
Confusion
Myoclonus
Paresthesia
Vertigo
Headache
Special Senses Hearing Loss
Tinnitus
Respiratory Chest Discomfort
Dyspnea
Hyperventilation
Thoracic Spine Pain
Cardiovascular Palpitations
Tachycardia
Skin Erythema Multiforme
Angioneurotic Edema
Flushing
Cyanosis
Hyperhidrosis
Skin Texture Changes
Candidiasis
Pruritus Vulvae
Local Administration site Infused vein infection
Body as a Whole Polyarthralgia
Asthenia/Weakness
Renal Oliguria/Anuria
Polyuria
Table 6: Incidence (%)Adverse reactions that occurred in >1% of PRIMAXIN-treated pediatric patients (greater than or equal to 3 months of age) of Adverse Reactions Reported During Clinical Investigations of Pediatric Patients Greater Than or Equal to 3 Months of Age Treated with PRIMAXIN
Body System Adverse Reactions Frequency (%)
Local Administration Site Phlebitis 2.2%
Intravenous Site Irritation 1.1%
Gastrointestinal Diarrhea 3.9%
Gastroenteritis 1.1%
Vomiting 1.1%
Skin Rash 2.2%
Renal Urine Discoloration 1.1%
Table 7: Incidence (%)Adverse reactions that occurred in >1% of PRIMAXIN-treated pediatric patients (neonates to 3 months of age) of Adverse Reactions Reported During Clinical Investigations of Pediatric Patients Neonates to 3 Months of Age Treated with PRIMAXIN
Body System Adverse Reactions Frequency (%)
Gastrointestinal Diarrhea 3%
CNS Convulsions 5.9%
Cardiovascular Tachycardia 1.5%
Skin Rash 1.5%
Body as a Whole Oral Candidiasis 1.5%
Renal Oliguria/Anuria 2.2%
Table 8: Adverse Reactions Identified During Post Approval Use of PRIMAXIN
Body System Adverse Reactions
Gastrointestinal Hepatitis (including fulminant hepatitis)
Hepatic failure
Jaundice
Staining of the teeth and/or tongue
Hematologic Pancytopenia
Bone marrow depression
Thrombocytopenia
Neutropenia
Leukopenia
Hemolytic anemia
CNS Tremor
Psychic disturbances including hallucinations
Dyskinesia
Agitation
Special Senses Taste perversion
Skin Stevens-Johnson syndrome
Toxic epidermal necrolysis
Body as a whole Drug fever
Renal Acute renal failure
Urine discoloration

Monitoring parameters

  • CrCl for dose; seizures, myoclonus and confusion, especially at CrCl 30 or less, on dialysis, or with CNS disease (label); valproate levels if coadministered. Kidney
  • CrCl for dose
  • Neurologic status (seizure risk)
  • Valproate levels if coadministered
renalcarematters.com, reviewed

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary Available data from a small number of postmarketing cases with PRIMAXIN use in pregnancy are not sufficient to identify any drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. Developmental toxicity studies with imipenem and cilastatin sodium (alone or in combination) administered to mice, rats, rabbits, and monkeys at doses 0.4 to 2.9 times the recommended human dose (RHD), (based on body surface area), showed no drug-induced fetal malformations.

Embryofetal development studies with imipenem/cilastatin administered to cynomolgus monkeys at doses similar to the RHD (based on body surface area) showed an increase in embryonic loss (see Data). The background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes.

The background risk of major birth defects is 2-4% and of miscarriage is 15-20% of clinically recognized pregnancies within the general population. Data Animal Data Reproductive toxicity studies with imipenem and cilastatin (alone or in combination) administered to mice, rats, and rabbits showed no evidence of effects on embryofetal (mice, rats and rabbits) or pre/postnatal (rats) development.

Imipenem was administered intravenously to rats (gestation days (GD) 7 to 17) and rabbits (GD 6 to 18) at doses up to 900 and 60 mg/kg/day, respectively, approximately 2.9 and 0.4 times the RHD (based on body surface area). Cilastatin was administered subcutaneously to rats (GD 6 to 17) and intravenously to rabbits (GD 6 to 18) at doses up to 1000 and 300 mg/kg/day, respectively, approximately 3.2 and 1.9 times the RHD (based on body surface area).

Imipenem/cilastatin was administered intravenously to mice at doses up to 320 mg/kg/day (GD 6 to 15). In two separate studies, imipenem/cilastatin was administered to rats (GD 6 to 17 and GD 15 to day 21 postpartum) both intravenously at doses up to 80 mg/kg/day and subcutaneously at 320 mg/kg/day. The higher dose is approximately equal to the RHD (based on body surface area).

Imipenem/cilastatin administered intravenously to pregnant cynomolgus monkeys during organogenesis at 100 mg/kg/day, approximately 0.6 times the RHD (based on body surface area), at an infusion rate mimicking human clinical use, was not associated with fetal malformations, but there was an increase in embryonic loss relative to controls. Imipenem/cilastatin administered to pregnant cynomolgus monkeys during organogenesis at 40 mg/kg/day by bolus intravenous injection caused significant maternal toxicity including death and embryofetal loss.

Mechanism of action

12.1 Mechanism of Action PRIMAXIN is a combination of imipenem and cilastatin. Imipenem is a penem antibacterial drug [see Microbiology (12.4)]. Cilastatin is a renal dehydropeptidase inhibitor that limits the renal metabolism of imipenem.

US FDA label

Pharmacokinetics

Key PK parameters

Time to peak31 to 49 mcg/mL (500 mg) and 56 to 88 mcg/mL (1 g) after a 20-minute infusion
Half-lifeAbout 1 hour for each component
Protein bindingImipenem about 20%; cilastatin about 40%
Metabolism (CYP, transporters)Cilastatin blocks renal metabolism of imipenem
Renal excretion kidneyAbout 70% of each component in urine within 10 hours
Dialyzability kidneyYes (both components; label)
renalcarematters.com, reviewed
Half-life and elimination (verbatim, US label)

Elimination The plasma half-life of each component is approximately 1 hour.

Approximately 70% of the administered imipenem is recovered in the urine within 10 hours after which no further urinary excretion is detectable.

Pediatric Patients Doses of 25 mg/kg/dose in patients 3 months to <3 years of age, and 15 mg/kg/dose in patients 3-12 years of age were associated with mean trough plasma concentrations of imipenem of 1.1±0.4 mcg/mL and 0.6±0.2 mcg/mL following multiple 60-minute infusions, respectively; trough urinary concentrations of imipenem were in excess of 10 mcg/mL for both doses.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Intravenous infusion of PRIMAXIN over 20 minutes results in peak plasma levels of imipenem antimicrobial activity that range from 21 to 58 mcg/mL for the 500 mg dose, and from 41 to 83 mcg/mL for the 1000 mg dose. At these doses, plasma levels of imipenem antimicrobial activity decline to below 1 mcg/mL or less in 4 to 6 hours.

Peak plasma levels of cilastatin following a 20-minute intravenous infusion of PRIMAXIN range from 31 to 49 mcg/mL for the 500 mg dose, and from 56 to 88 mcg/mL for the 1000 mg dose. Distribution The binding of imipenem to human serum proteins is approximately 20% and that of cilastatin is approximately 40%. Imipenem has been shown to penetrate into human tissues, including vitreous humor, aqueous humor, lung, peritoneal fluid, CSF, bone, interstitial fluid, skin, and fascia.

As there are no adequate and well-controlled studies of imipenem treatment in these additional body sites, the clinical significance of these tissue concentration data is unknown. After a 1 gram dose of PRIMAXIN, the following average levels of imipenem were measured (usually at 1 hour post dose except where indicated) in the tissues and fluids listed in Table 9: Table 9: Average Levels of Imipenem Tissue or Fluid N Imipenem Level mcg/mL or mcg/g Range Vitreous Humor 3 3.4 (3.5 hours post dose) 2.88–3.6 Aqueous Humor 5 2.99 (2 hours post dose) 2.4–3.9 Lung Tissue 8 5.6 (median) 3.5–15.5 Sputum 1 2.1 — Pleural 1 22.0 — Peritoneal 12 23.9 S.D.±5.3 (2 hours post dose) — Bile 2 5.3 (2.25 hours post dose) 4.6–6.0 CSF (uninflamed) 5 1.0 (4 hours post dose) 0.26–2.0 CSF (inflamed) 7 2.6 (2 hours post dose) 0.5–5.5 Fallopian Tubes 1 13.6 — Endometrium 1 11.1 — Myometrium 1 5.0 — Bone 10 2.6 0.4–5.4 Interstitial Fluid 12 16.4 10.0–22.6 Skin 12 4.4 NA Fascia 12 4.4 NA Metabolism Imipenem, when administered alone, is metabolized in the kidneys by dehydropeptidase I, resulting in relatively low levels in urine.

Cilastatin, an inhibitor of this enzyme, effectively prevents renal metabolism of imipenem so that when imipenem and cilastatin sodium are given concomitantly, adequate antibacterial levels of imipenem are achieved in the urine. Elimination The plasma half-life of each component is approximately 1 hour. Approximately 70% of the administered imipenem is recovered in the urine within 10 hours after which no further urinary excretion is detectable.

Urine concentrations of imipenem in excess of 10 mcg/mL can be maintained for up to 8 hours with PRIMAXIN at the 500 mg dose. Approximately 70% of the cilastatin sodium dose is recovered in the urine within 10 hours of administration of PRIMAXIN. PRIMAXIN is hemodialyzable [see Overdosage (10)]. No accumulation of imipenem/cilastatin in plasma or urine is observed with regimens administered as frequently as every 6 hours in patients with normal renal function.

Specific Populations Geriatric Patients In healthy elderly volunteers (65 to 75 years of age with normal renal function for their age), the pharmacokinetics of a single dose of imipenem 500 mg and cilastatin 500 mg administered intravenously over 20 minutes are consistent with those expected in subjects with slight renal impairment for which no dosage alteration is considered necessary. The mean plasma half-lives of imipenem and cilastatin are 91±7 minutes and 69±15 minutes, respectively.

Multiple dosing has no effect on the pharmacokinetics of either imipenem or cilastatin, and no accumulation of imipenem/cilastatin is observed. Pediatric Patients Doses of 25 mg/kg/dose in patients 3 months to <3 years of age, and 15 mg/kg/dose in patients 3-12 years of age were associated with mean trough plasma concentrations of imipenem of 1.1±0.4 mcg/mL and 0.6±0.2 mcg/mL following multiple 60-minute infusions, respectively; trough urinary concentrations of imipenem were in excess of 10 mcg/mL for both doses.

These doses have provided adequate plasma and urine concentrations for the treatment of non-CNS infections. In a dose-ranging study of smaller premature infants (670-1,890 g) in the first week of life, a dose of 20 mg/kg q12h by 15-30 minutes infusion was associated with mean peak and trough plasma imipenem concentrations of 43 mcg/mL and 1.7 mcg/mL after multiple doses, respectively.

However, moderate accumulation of cilastatin in neonates may occur following multiple doses of PRIMAXIN. The safety of this accumulation is unknown.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. PRIMAXIN IV · Merck Sharp & Dohme LLC [US FDA-approved label, version 35, July 5, 2024]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f41d8abd-7792-4918-1b93-bd83ea01955e
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. Merck Sharp & Dohme LLC. (2024). PRIMAXIN I.V. (imipenem and cilastatin) for injection [Prescribing information; US FDA-approved label, NDA050587, set ID f41d8abd-7792-4918-1b93-bd83ea01955e, version effective July 5, 2024]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f41d8abd-7792-4918-1b93-bd83ea01955e
  4. Li, L., Li, X., Xia, Y., Chu, Y., Zhong, H., Li, J., Liang, P., Bu, Y., Zhao, R., Liao, Y., Yang, P., Lu, X., & Jiang, S. (2020). Recommendation of antimicrobial dosing optimization during continuous renal replacement therapy. Frontiers in Pharmacology, 11, Article 786. https://doi.org/10.3389/fphar.2020.00786
  5. Li, P. K.-T., Chow, K. M., Cho, Y., Fan, S., Figueiredo, A. E., Harris, T., Kanjanabuch, T., Kim, Y.-L., Madero, M., Malyszko, J., Mehrotra, R., Okpechi, I. G., Perl, J., Piraino, B., Runnegar, N., Teitelbaum, I., Wong, J. K.-W., Yu, X., & Johnson, D. W. (2022). ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Peritoneal Dialysis International, 42(2), 110–153. https://doi.org/10.1177/08968608221080586

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .